Eli Lilly announced results from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN trials on May 12, 2026, showing effective weight loss maintenance.
In SURMOUNT-MAINTAIN, participants on Zepbound maximum tolerated dose (MTD) maintained all prior weight loss; those reduced to 5 mg Zepbound maintained all but 5.6 kg after 52 weeks.
In ATTAIN-MAINTAIN, switchers from Wegovy MTD to Foundayo maintained all but 0.9 kg; from Zepbound MTD to Foundayo maintained all but 5.0 kg after 52 weeks.
Trials presented at 33rd European Congress on Obesity and published in The Lancet and Nature Medicine.
Foundayo is a once-daily oral GLP-1; Zepbound maintenance doses include 5 mg, 10 mg, or 15 mg.